OBJECTIVE: Detailed characterization of progesterone and ovulation across the menopausal transition provides insight into conception risk and mechanisms of reproductive aging. METHODS: Participants (n = 108, aged 25-58 y) collected daily urine specimens for 6-month intervals in each of 5 consecutive years. Specimens were assayed for pregnanediol glucuronide (PDG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estrone glucuronide (E1G). Reproductive stage was determined using cycle length variance. A hierarchical algorithm was used to identify ovulation. Linear mixed-effects models estimated (1) the frequency and day of ovulation by age and stage; (2) differences in FSH, LH, and E1G levels between ovulatory (O) and anovulatory (AO) cycles; and (3) total PDG levels and PDG levels in O cycles by age and stage. RESULTS: The probability of AO cycles increased across the perimenopause (P < 0.0001); reproductive stage was a stronger predictor than age of the probability of anovulation. Most cycles in late perimenopause were AO (>60%), but one quarter of cycles longer than 60 days were O. Average day of ovulation was later in the late perimenopause (mean [SD] cycle day, 27 [25] d) compared with the premenopause. FSH and LH levels were higher and E1G levels were lower in AO than O cycles (P < 0.0001 for each). Total PDG decreased in the late perimenopause, but 95th percentile PDG in O cycles declined steadily across the transition. CONCLUSIONS: Exposure to the risk of conception in women experiencing cycles long enough to classify them as late perimenopausal is far from negligible. Reproductive stage is more informative than age about PDG levels and the likelihood of anovulation.
OBJECTIVE: Detailed characterization of progesterone and ovulation across the menopausal transition provides insight into conception risk and mechanisms of reproductive aging. METHODS:Participants (n = 108, aged 25-58 y) collected daily urine specimens for 6-month intervals in each of 5 consecutive years. Specimens were assayed for pregnanediol glucuronide (PDG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estroneglucuronide (E1G). Reproductive stage was determined using cycle length variance. A hierarchical algorithm was used to identify ovulation. Linear mixed-effects models estimated (1) the frequency and day of ovulation by age and stage; (2) differences in FSH, LH, and E1G levels between ovulatory (O) and anovulatory (AO) cycles; and (3) total PDG levels and PDG levels in O cycles by age and stage. RESULTS: The probability of AO cycles increased across the perimenopause (P < 0.0001); reproductive stage was a stronger predictor than age of the probability of anovulation. Most cycles in late perimenopause were AO (>60%), but one quarter of cycles longer than 60 days were O. Average day of ovulation was later in the late perimenopause (mean [SD] cycle day, 27 [25] d) compared with the premenopause. FSH and LH levels were higher and E1G levels were lower in AO than O cycles (P < 0.0001 for each). Total PDG decreased in the late perimenopause, but 95th percentile PDG in O cycles declined steadily across the transition. CONCLUSIONS: Exposure to the risk of conception in women experiencing cycles long enough to classify them as late perimenopausal is far from negligible. Reproductive stage is more informative than age about PDG levels and the likelihood of anovulation.
Authors: M Weinstein; T Gorrindo; A Riley; J Mormino; J Niedfeldt; B Singer; G Rodríguez; J Simon; S Pincus Journal: Am J Epidemiol Date: 2003-10-15 Impact factor: 4.897
Authors: John F Randolph; MaryFran Sowers; Ellen B Gold; Beth A Mohr; Judith Luborsky; Nanette Santoro; Daniel S McConnell; Joel S Finkelstein; Stanley G Korenman; Karen A Matthews; Barbara Sternfeld; Bill L Lasley Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Kathleen A O'Connor; Eleanor Brindle; Darryl J Holman; Nancy A Klein; Michael R Soules; Kenneth L Campbell; Fortüne Kohen; Coralie J Munro; Jane B Shofer; Bill L Lasley; James W Wood Journal: Clin Chem Date: 2003-07 Impact factor: 8.327
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: J Clin Endocrinol Metab Date: 2012-02-16 Impact factor: 5.958
Authors: Jennifer L Gordon; Susan S Girdler; Samantha E Meltzer-Brody; Catherine S Stika; Rebecca C Thurston; Crystal T Clark; Beth A Prairie; Eydie Moses-Kolko; Hadine Joffe; Katherine L Wisner Journal: Am J Psychiatry Date: 2015-01-13 Impact factor: 18.112
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: Fertil Steril Date: 2012-02-16 Impact factor: 7.329
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: Menopause Date: 2012-04 Impact factor: 2.953
Authors: Stephanie V Koebele; Sarah E Mennenga; Ryoko Hiroi; Alicia M Quihuis; Lauren T Hewitt; Mallori L Poisson; Christina George; Loretta P Mayer; Cheryl A Dyer; Leona S Aiken; Laurence M Demers; Catherine Carson; Heather A Bimonte-Nelson Journal: Horm Behav Date: 2016-10-26 Impact factor: 3.587